EIKN Valuation

Eikon Therapeutics Inc (EIKN) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of Eikon Therapeutics Inc (EIKN) is between -- to -- according to relative valuation method.

EIKN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Eikon Therapeutics Inc (EIKN) is between -- to -- according to relative valuation method.

The average P/S ratio for EIKN's competitors is 1.20, providing a benchmark for relative valuation. Eikon Therapeutics Inc Corp (EIKN) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

As of Mar 02 2026, Eikon Therapeutics Inc (EIKN) has a P/B ratio of NaN. This indicates that the market values EIKN at NaN times its book value.

As of Mar 02 2026, Eikon Therapeutics Inc (EIKN) has a FCF Yield of NaN%. This means that for every dollar of Eikon Therapeutics Inc's market capitalization, the company generates NaN cents in free cash flow.

As of Mar 02 2026, Eikon Therapeutics Inc (EIKN) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Eikon Therapeutics Inc's expected earnings over the next 12 months.

As of Mar 02 2026, Eikon Therapeutics Inc (EIKN) has a Forward P/S ratio of NaN. This means the market is valuing EIKN at $NaN for every dollar of expected revenue over the next 12 months.